Real-World study tests migraine Pill's consistency and satisfaction

NCT ID NCT06467370

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study follows adults with migraine who have been prescribed rimegepant (a dissolving tablet) for acute attacks. Researchers want to see how consistently the drug provides meaningful pain relief across multiple attacks and how satisfied people are with it. The study also looks at whether rimegepant works well for those already taking other migraine preventives like CGRP antibodies or Botox. Participants track their symptoms and relief in a daily diary over 30 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rimegepant (oral dissolving tablet)
What this could lead to: If successful, this study could show how reliably rimegepant eases migraine attacks in real-world use, especially for people also taking other preventives.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by factors like patient expectations or other treatments. It does not test a new drug or compare rimegepant to a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Locations

Pfizer

New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.